Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Xiaoxiang Chen
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04556071CT.gov Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endocrine Gland Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Xiaoxiang Chen | P2 | BB · 64 |
| Dexasone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Denosumab | Amgen | P2 | B |
| Trabectedin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | B |
| Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer | NantCell, Inc. | P3 | CCC |
| Teonanacatl | University Health Network, Toronto | P2 | CCC |
| Niraparib | Xiaoxiang Chen | P2 | CCC |
| Capecitabine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | CCC |
| Pralsetinib, Trans- | Hoffmann-La Roche | P1/2 | CCC |
+4 more in the Endocrine Gland Neoplasm cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DexasoneJohnson & Johnson Pharmaceutical Research & Development, L.L.C.B
- DenosumabAmgenB
- TrabectedinJohnson & Johnson Pharmaceutical Research & Development, L.L.C.B
- Immunoglobulin G, Anti-(Human Insulin-Like Growth Factor I Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, DimerNantCell, Inc.CCC
- TeonanacatlUniversity Health Network, TorontoCCC
Citation
Floatz Terminal. Irinotecan in Endocrine Gland Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-endocrine-gland-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →